(Date:12/1/2008)...h wraps up successful disaster relief campaign , ... -- The American Red Cross is asking people across...0 million in 30 days. This holiday season push wil... the Red Cross Campaign for Disaster Relief. Alrea...ce its launch in September, and the Red Cross hope...
(Date:12/1/2008)...Dec. 1 Medication therapy manageme...complished professionals to its,advisory board. ,...include Martin Makary, M.D.;,Michael Burcham; and...of,advisors that has helped PharmMD launch and ho...medication error, misuse, overuse and abuse. MTM ...
(Date:12/1/2008)...ec. 1 The United States...s new right hand on Saturday, November 29, as Dr. ...n, changed the bandages. , , "Wow, it looks...rom his room at Jewish Hospital. "It,s awesome," ... , Hondusky, a New York resident, went on to s...
(Date:12/1/2008)...e implant makes it more difficult to treat the mal.... 1 (HealthDay News) -- Women who have had their b...osed with early-stage breast cancer may be treated...tment known as brachytherapy, according to an Ariz...allenge to take care of these augmented women," sa...
Breaking Medicine News(10 mins):Health News:Red Cross Asks America to Help Raise $30 Million in 30 Days 2Health News:Red Cross Asks America to Help Raise $30 Million in 30 Days 3Health News:PharmMD Expands Advisory Board 2Health News:Fifth U.S. Hand Transplant Patient Gets Look at New Hand 2Health News:Radioactive 'Seed' Rx Helps Women With Implants Fight Breast Cancer 2Health News:Radioactive 'Seed' Rx Helps Women With Implants Fight Breast Cancer 3(Date:11/28/2008)..., Nov. 28 Eli Lilly and ...ntal New Drug Application (sNDA) from,the U.S. Fo...duloxetine HCl),for the management of chronic pai... first half of 2009, adding data from a recently c... pain of the knee. , The decision does not ...
(Date:11/25/2008)...eness can improve recovery , , Audio and We...lable on the Mayo Clinic News Blog. Please see the... ROCHESTER, Minn., Nov. 25 /PRNewswire-USNewswir...ke patients don,t think they,re having a stroke --...their condition worsens. The findings appear in th...
(Date:11/25/2008)...alif., Nov. 25 Pharmacyc... the company has completed a Phase 1,clinical tri...lass,small-molecule Factor VIIa inhibitor. The tr...ers to evaluate the safety and pharmacologic effec...483 resulted in a linear dose,response in the Int...
(Date:11/24/2008)...N.J., Nov. 24 Leaders of...provided an update for investors on the company,s ...ive portfolio that includes 46 new entities in cli...preclinical studies. , , "Research and deve...-Plough as we continue our transformation," said F...
Breaking Medicine Technology:Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Lettuce leafy greens and E coli 370 1Lettuce leafy greens and E coli 370 2Two studies published in the Lancet 366 1Two studies published in the Lancet 366 2New Study Findings Confirm CLEXANE 28R 29 LOVENOX 28R 29 Long Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 310 1New Study Findings Confirm CLEXANE 28R 29 LOVENOX 28R 29 Long Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 310 2New Study Findings Confirm CLEXANE 28R 29 LOVENOX 28R 29 Long Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 310 3New Study Findings Confirm CLEXANE 28R 29 LOVENOX 28R 29 Long Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 310 4New Study Findings Confirm CLEXANE 28R 29 LOVENOX 28R 29 Long Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 310 5Report recommends off site disposal of secondary waste 307 1Report recommends off site disposal of secondary waste 307 2Report recommends off site disposal of secondary waste 307 3Report recommends off site disposal of secondary waste 307 4...WSWIRE) -- New data,presented at ECCMID highlight ...f Basilea,s (SWX:BSLN) two late-stage,drug candida...ed,both for ceftobiprole, the first anti-MRSA broa..., and for isavuconazole, a,novel azole for the tre...her data on their respective breadths of spectrum,...
...- Novagali Pharma, an,emerging ophthalmic pharmace...nces today positive results from the Phase III,cli...om Vernal,Keratoconjunctivitis (VKC). In this orph...gns of disease improved in patients,receiving Veka...),was excellent. , VKC is a severe form of chronic...
Other Medicine Technology:Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 2Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 4Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 5Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 6Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 7Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis 2...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: